Form 8-K - Current report:
SEC Accession No. 0001558370-25-000151
Filing Date
2025-01-13
Accepted
2025-01-13 07:30:24
Documents
15
Period of Report
2025-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mxct-20250113x8k.htm   iXBRL 8-K 38173
2 EX-99.1 mxct-20250113xex99d1.htm EX-99.1 19425
3 GRAPHIC mxct-20250113xex99d1001.jpg GRAPHIC 4538
  Complete submission text file 0001558370-25-000151.txt   193377

Data Files

Seq Description Document Type Size
4 EX-101.SCH mxct-20250113.xsd EX-101.SCH 3417
5 EX-101.LAB mxct-20250113_lab.xml EX-101.LAB 16578
6 EX-101.PRE mxct-20250113_pre.xml EX-101.PRE 10717
17 EXTRACTED XBRL INSTANCE DOCUMENT mxct-20250113x8k_htm.xml XML 5020
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40674 | Film No.: 25524808
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)